Candida albicans biofilm formation and its clinical consequences
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In the last several years there has been increasing recognition in the Microbiology field that biofilms constitute the predominant mode of growth for most microorganisms in their natural habitats [1, 2]. Different from planktonic (free floating) organisms, biofilms can be defined as structured microbial communities, attached to a biotic or abiotic surface, and most frequently encapsulated within a matrix of self-produced exopolymeric material. Most importantly, the same is also true for the relative minority of microorganisms that are pathogenic to humans, and according to the CDC today it is estimated that about 65% of all treated infections are associated with microbial biofilm formation on the surface of tissues, organs or medical devices. Biofilm formation carries important clinical implications, as sessile cells typically display increased levels of resistance to most antibiotics and also to host defence mechanisms. In addition, the protective structure of a biofilm provides cells with a safe sanctuary in which they are able to withstand adverse environmental conditions. In essence, biofilms act as reservoirs for persistent sources of infection. Thus, the net effect is that microbial biofilms negatively impact the health of a growing number of patients, that ultimately translates to a soaring financial burden to our health care system [3]. Candida albicans is no exception to this rule, and this often benign commensal of humans is now the fungal species most frequently associated with formation of biofilms affecting different types of immunosuppressed patients [4]. There is little doubt that different manifestations of candidiasis, including oropharyngeal candidiasis, denture stomatitis, endocarditis and catheter-related candidemia and candiduria, among others, are intimately associated with the formation of biofilms on host surfaces and/or implantable medical devices [5, 6]. A variety of biomaterials used in clinical practice are able to support biofilm formation by Candida and, ironically, the increase in candidiasis in recent years (now the third to fourth most common nosocomial infection in US hospitals and abroad) has been virtually concomitant with the increase in use of a broad range of medical implant devices, mostly in immunocompromised patients [7, 8]. The increasing awareness of the importance of Candida biofilms is reflected by the number of publications on this topic: a simple PubMed search using the terms “Candida” and “biofilm” returned 549 articles, with over 90% of these articles having been published in the last ten years. But, how does C. albicans form a biofilm and what are the most important characteristics linked to biofilm formation? In order to answer these fundamental questions multiple groups of investigators have developed different models of C. albicans biofilm formation, with varying degrees of sophistication, both in vitro and most recently in vivo. Using these models and now armed with state of the art analytical techniques (including advanced microscopy techniques, genomics and proteomics, etc.) researchers have been able to shed some light on the structural characteristics and molecular mechanisms governing biofilm formation by this opportunistic pathogenic fungus [4]. From these studies it is now clear that these biofilms are not a simple accumulation of cells, but rather highly structured microbial communities, postulated to represent an optimal spatial arrangement to facilitate the influx of nutrients and disposal of waste products. In general, most investigators in the field agree that C. albicans biofilm development encompasses different phases, including initial adherence, colonization, proliferation, maturation and ultimately dispersion so that the “biofilm life-cycle” can be repeated all over again [4, 9, 10]. Mature C. albicans biofilms typically consist of an intricate network of yeasts, hyphae and pseudohyphae within ramifying water channels and are encased within exopolymeric material. They exhibit a rather complex three-dimensional architecture, likely indicative of a high degree of specialization reminiscent of what is found in primitive tissue. Our current understanding at the molecular level of the mechanisms controlling C. albicans biofilm formation is still somewhat limited; however, in recent years studies by multiple groups of investigators have begun to unravel some of the major driving forces behind the transition to the biofilm life style [4, 11]. Besides some insights into biofilm metabolism, these studies have revealed a pivotal role for morphogenetic conversions (the ability to reversibly switch between yeast and filamentous forms in response to different environmental stimuli), adhesive interactions and quorum sensing mechanisms in C. albicans biofilm development, with also some very important implications in mating. Two very interesting reviews published in this very issue of this Journal provide readers with up to date information on the Ras/cAMP/PKA signaling pathway that regulates filamentation and virulence in C. albicans and on the role of farnesol as a quorum sensing molecule: both of these phenomena are critical for the C. albicans biofilm mode of growth. For example, the C. albicansΔefg1 mutant strain is locked in the yeast form and forms only a rudimentary (monolayer) biofilm, thus pointing to the Efg1p regulator protein (a main component of the Ras/cAMP/PKA signaling pathway) as a key factor in C. albicans biofilm formation [12]. Moreover, HWP1 and ALS3, whose expression is under the control of Efg1p, encode hypha-specific cell wall proteins that play complementary adhesive functions critical in C. albicans biofilm development [13]. Likewise, farnesol, and other autoregulatory molecules also control C. albicans biofilm formation via quorum sensing mechanisms [14, 15]. As mentioned before, C. albicans biofilm formation carries important negative clinical implications, mostly due to the fact that cells in biofilms are recalcitrant to antifungal therapy. As such, biofilm formation is now widely considered one of the major virulence attributes of C. albicans and a key contributing factor to the unacceptably high mortality rates associated with candidiasis. A plethora of articles have now been published reporting that fungal biofilms show intrinsic resistance to azole derivatives and display high levels of resistance against polyenes, two of the most common classes of antifungal agents. Contrary to these observations echinocandins, a new class of antifungal agents targeting cell wall glucan, seem to display excellent anti-biofilm activity at therapeutic concentrations [4, 16]. Antifungal drug resistance of C. albicans cells within biofilms is likely multifactorial and, among other mechanisms, may be due to i) metabolic and physiological state of sessile fungal cells, ii) elevated cellular density within the biofilm; iii) the protective effect of the biofilm matrix, including presence of glucans which may bind to molecules of certain antifungal agents (azoles) ; iv) differential expression of genes linked to resistance, including those encoding efflux pumps; v) differences in sterol composition of the cell wall membrane; and vi) presence of a subpopulation of “persister” cells [4]. In conclusion, sessile C. albicans cells within biofilms possess distinct developmental properties and phenotypic characteristics that are in stark contrast to planktonic cells. Because of this, infections associated with C. albicans biofilm formation represent an escalating problem in health care and negatively impact the health of an increasing number of individuals as progress in modern medicine prolong the lives of severely ill patients. The increased recognition by the research and medical community of the role that biofilms play during infection should, without any doubt, lead to major advances in the diagnosis, prevention and treatment of biofilm-associated candidiasis in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“A variety of biomaterials used in clinical practice are able to support biofilm formation by Candida and, ironically, the increase in candidiasis in recent years (now the third to fourth most common nosocomial infection in US hospitals and abroad) has been virtually concomitant with the increase in use of a broad rang…”
BackgroundEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“A variety of biomaterials used in clinical practice are able to support biofilm formation by Candida and, ironically, the increase in candidiasis in recent years (now the third to fourth most common nosocomial infection in US hospitals and abroad) has been virtually concomitant with the increase in use of a broad rang…”
BackgroundChandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578 · cited 1×
“albicans biofilm development encompasses different phases, including initial adherence, colonization, proliferation, maturation and ultimately dispersion so that the “biofilm life-cycle” can be repeated all over again [4,9,10].”
BackgroundBiofilm Formation: A Clinically Relevant Microbiological Process
Donlan, R. M. (2001) · Clinical Infectious Diseases · doi:10.1086/322972 · Cited by 1,343
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055 · cited 1×
“There is little doubt that different manifestations of candidiasis, including oropharyngeal candidiasis, denture stomatitis, endocarditis and catheter-related candidemia and candiduria, among others, are intimately associated with the formation of biofilms on host surfaces and/or implantable medical devices [5,6].”
BackgroundRamage, G., Saville, S. P., Thomas, D. P., & López-Ribot, J. L. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.4.633-638.2005 · Cited by 678
Self-citationCandida biofilms on implanted biomaterials: a clinically significant problem
Ramage, G., MartÃnez, J. P., & López-Ribot, J. L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00117.x · Cited by 575 · cited 1×
“There is little doubt that different manifestations of candidiasis, including oropharyngeal candidiasis, denture stomatitis, endocarditis and catheter-related candidemia and candiduria, among others, are intimately associated with the formation of biofilms on host surfaces and/or implantable medical devices [5,6].”
BackgroundComplementary Adhesin Function in C. albicans Biofilm Formation
Nobile, C. J., Schneider, H. A., Nett, J. E., Sheppard, D. C., Filler, S. G., Andes, D. R., & Mitchell, A. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.06.034 · Cited by 351
In Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Self-citationThe Ras/cAMP/PKA signaling pathway and virulence in Candida albicans
Hogan, D. A., & Sundstrom, P. (2009) · Future Microbiology · doi:10.2217/fmb.09.106 · Cited by 186
Cited by
Fungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323
“Moreover, Candida biofilm formation is clinically important as sessile communities of yeasts are the reservoirs originating the spread of fungal infections [8].”
BackgroundSelf-citationCandida albicans biofilm growth and dispersal: contributions to pathogenesis
Wall, G., Montelongo-Jauregui, D., Vidal Bonifacio, B., Lopez-Ribot, J. L., & Uppuluri, P. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.001 · Cited by 263
“albicans to form an organized consortia of cells called biofilms, on indwelling medical devices [3].”
BackgroundSelf-citationDominguez, E., Zarnowski, R., Sanchez, H., Covelli, A. S., Westler, W. M., Azadi, P., Nett, J., Mitchell, A. P., & Andes, D. R. (2018) · mBio · doi:10.1128/mbio.00451-18 · Cited by 77
A novel flow cytometric protocol for assessment of yeast cell adhesion
Silva‐Dias, A., Miranda, I. M., Rocha, R., Monteiro‐Soares, M., Salvador, A., Rodrigues, A. G., & Pina‐Vaz, C. (2012) · Cytometry Part A · doi:10.1002/cyto.a.21170 · Cited by 19
Metadata
- Authors
- Uppuluri, P., Pierce, C. G., & López-Ribot, J. L.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2009-12
- Volume
- 4
- Issue
- 10
- Pages
- 1235-1237
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2085387290
- Cited by
- 76
- References
- 10
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Candida albicans biofilm formation and its clinical consequences. https://app.cochat.ai/papers/10.2217/fmb.09.85
- The paper
- Uppuluri, P., Pierce, C. G., & López-Ribot, J. L. (2009). Candida albicans biofilm formation and its clinical consequences. Future Microbiology. https://doi.org/10.2217/fmb.09.85
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.